Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

Published:2016-11-23 Issue:1 Volume:17 Page:47-59
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Valecha Gautam Kishore¹,Vennepureddy Adarsh²,Ibrahim Uroosa²,Safa Firas¹,Samra Bachar³,Atallah Jean Paul²

Affiliation:

1. Department of Medicine, Staten Island University Hospital, Staten Island, NY, USA

2. Department of Hematology-Oncology, Staten Island University Hospital, Staten Island, NY, USA

3. Department of Hematology-Oncology, SUNY Downstate Medical Center, Brooklyn, NY, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2017.1259574

Reference53 articles.

1. Innate and adaptive immune cells in the tumor microenvironment

2. Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer

3. THE B7 FAMILY REVISITED

4. The State of the Art in Non–Small Cell Lung Cancer Immunotherapy

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias;Lung Cancer;2024-06

2. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?;Investigational New Drugs;2024-02-22

3. NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy;Frontiers in Immunology;2024-02-07

4. Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency;Translational Oncology;2023-12

5. First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab？;2023-09-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3